The Medicines Company Profile (NASDAQ:MDCO)

About The Medicines

The Medicines logoThe Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company's products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MDCO
  • CUSIP: 58468810
Key Metrics:
  • Previous Close: $38.81
  • 50 Day Moving Average: $37.25
  • 200 Day Moving Average: $34.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.56
  • P/E Growth: -0.39
  • Market Cap: $2.78B
  • Outstanding Shares: 69,710,000
  • Beta: 0.67
Additional Links:
Companies Related to The Medicines:

Analyst Ratings

Consensus Ratings for The Medicines (NASDAQ:MDCO) (?)
Ratings Breakdown: 3 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $48.75 (22.46% upside)

Analysts' Ratings History for The Medicines (NASDAQ:MDCO)
DateFirmActionRatingPrice TargetDetails
8/15/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingBuy$45.00View Rating Details
8/2/2016Citigroup Inc.Reiterated RatingHoldView Rating Details
7/19/2016Leerink SwannReiterated RatingBuyView Rating Details
7/12/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
7/12/2016Bank of America Corp.Reiterated RatingBuyView Rating Details
6/15/2016Jefferies GroupReiterated RatingBuy$43.00View Rating Details
6/2/2016Chardan CapitalReiterated RatingBuyView Rating Details
3/31/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
3/24/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
11/6/2015Piper Jaffray Cos.Reiterated RatingNeutral$28.00 -> $31.00View Rating Details
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details
11/20/2014Credit Suisse Group AGUpgradeNeutral -> Outperform$27.00 -> $33.00View Rating Details
(Data available from 8/27/2014 forward)


Earnings History for The Medicines (NASDAQ:MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.82)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.65)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.82)$0.20$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.12)$0.18$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.02)($0.08)$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.07)($0.08)$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for The Medicines (NASDAQ:MDCO)
Current Year EPS Consensus Estimate: $-5.66 EPS
Next Year EPS Consensus Estimate: $-3.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.00)($0.76)($0.85)
Q2 20165($1.39)($0.74)($1.10)
Q3 20165($1.40)($0.76)($1.09)
Q4 20165($1.46)($0.77)($1.09)
(Data provided by Zacks Investment Research)


Dividend History for The Medicines (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for The Medicines (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for The Medicines (NASDAQ:MDCO)
News IconStock Trading Above Moving Averages: The Medicines Company (NASDAQ:MDCO) - Post News (NASDAQ:MDCO) - August 23 at 10:31 AM logoNoteworthy Friday Option Activity: NKE, MDCO, DVA (NASDAQ:MDCO) - August 19 at 6:02 PM logoAnalysts See The Medicines Company (NASDAQ:MDCO) Reporting EPS Of $-1.45 - (NASDAQ:MDCO) - August 18 at 6:12 PM logoMEDICINES CO /DE Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MDCO) - August 18 at 6:12 PM logoAnalysts See The Medicines Company (NASDAQ:MDCO) Reporting EPS Of $-1.45 (NASDAQ:MDCO) - August 17 at 6:18 PM logoThe Medicines Company (NASDAQ:MDCO) Reports Accounts Payable Of $26.723 (NASDAQ:MDCO) - August 16 at 9:24 AM logoThe Medicines Company (NASDAQ:MDCO) Reports Accounts Payable Of $26.723 - (NASDAQ:MDCO) - August 15 at 6:17 PM
News IconThe Medicines Company (NASDAQ:MDCO) To Report September 2016 Results - The Voice Registrar (NASDAQ:MDCO) - August 12 at 9:20 AM logoETF’s with exposure to The Medicines Co. : August 11, 2016 (NASDAQ:MDCO) - August 11 at 6:26 PM logoMEDICINES CO /DE Financials (NASDAQ:MDCO) - August 11 at 6:26 PM logoThe Medicines Company (NASDAQ:MDCO) Updated Price Targets ... - FTSE News (NASDAQ:MDCO) - August 9 at 6:21 PM logoBlueprint Medicines  beats by $0.03, beats on revenue (NASDAQ:MDCO) - August 9 at 7:16 AM logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:MDCO) - August 8 at 6:19 PM logoMEDICINES CO /DE Files SEC form 10-Q, Quarterly Report (NASDAQ:MDCO) - August 5 at 9:09 AM logoCome Take Your Medicine (Company) (NASDAQ:MDCO) - August 4 at 6:27 PM logoRevenue Update on The Medicines Company(NASDAQ:MDCO ... - Trade Calls (NASDAQ:MDCO) - August 3 at 6:27 PM logoLatest Price movements of Stocks: The Medicines Company (NASDAQ:MDCO) , Tandem Diabetes Care, Inc. (NASDAQ ... - Street Updates (NASDAQ:MDCO) - August 1 at 10:48 AM logoGSK and Google parent forge $715 million bioelectronic medicines firm - Reuters (NASDAQ:MDCO) - August 1 at 6:00 AM logoAdaptimmune Gets Access To Priority Medicines Regulatory Support For Its SPEAR T-cell Therapy (NASDAQ:MDCO) - July 28 at 2:40 PM logoThe Medicines Company (MDCO) Jumps 7.14% on July 27 ... - (NASDAQ:MDCO) - July 28 at 9:19 AM logoEdited Transcript of MDCO earnings conference call or presentation 27-Jul-16 12:30pm GMT (NASDAQ:MDCO) - July 27 at 9:11 PM logoMallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise? (NASDAQ:MDCO) - July 27 at 6:27 PM logoMedicines : posts 2Q profit (NASDAQ:MDCO) - July 27 at 6:27 PM logoThe Medicines Company Reports Second-Quarter 2016 Business and Financial Results (NASDAQ:MDCO) - July 27 at 7:48 AM logoMedicines Co. posts 2Q profit (NASDAQ:MDCO) - July 27 at 7:36 AM logoMerck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine (NASDAQ:MDCO) - July 25 at 10:16 AM logoEU watchdog flags faulty generic drug data, backs sales halt (NASDAQ:MDCO) - July 22 at 2:45 PM logoMylan And Biocon Says EMA Accept Its Regulatory Submission Of Biosimilar Pegfilgrastim (NASDAQ:MDCO) - July 21 at 1:25 PM
News IconThe Medicines Company (NASDAQ:MDCO): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:MDCO) - July 20 at 6:50 PM
News IconWere Analysts Bearish The Medicines Company (NASDAQ:MDCO) This Week? - Consumer Eagle (NASDAQ:MDCO) - July 20 at 6:50 PM logoCall buyers targeting Medicines Company (NASDAQ:MDCO) - July 20 at 8:14 AM logoWatch These 10 Huge Call Purchases In Wednesday Trade (NASDAQ:MDCO) - July 20 at 3:28 AM logoThe Medicines Company to Announce Second Quarter Financial Results on July 27 ... (NASDAQ:MDCO) - July 19 at 12:13 PM logoAccounts Payable For The Medicines Company (NASDAQ:MDCO) Stood At $15.526 - (NASDAQ:MDCO) - July 18 at 6:15 PM
News IconTrading Performance and Target Watch for The Medicines Company (NASDAQ:MDCO) - Press Telegraph (NASDAQ:MDCO) - July 18 at 11:26 AM logoEarnings Surprise in Focus: The Medicines Company (NASDAQ:MDCO) - Investor Newswire (NASDAQ:MDCO) - July 18 at 11:26 AM logoBRIEF-EMA classifies Advaxis cervical cancer drug as an 'advanced-therapy medicinal product' (NASDAQ:MDCO) - July 18 at 8:32 AM logoThe Medicines Company to Announce Second Quarter Financial Results on July 27, 2016 (NASDAQ:MDCO) - July 18 at 7:00 AM
News IconEMA to review Samsung Bioepis Humira biosim application - FiercePharma (NASDAQ:MDCO) - July 18 at 12:31 AM logoUPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy (NASDAQ:MDCO) - July 17 at 10:24 PM logoCan The Medicines Company (NASDAQ:MDCO) Surprise Analysts this Quarter? - Investor Newswire (NASDAQ:MDCO) - July 17 at 5:38 PM
News IconBiotech Battles Bacterial Threats (NASDAQ:MDCO) - July 17 at 10:25 AM
News IconBridger Management LLC Increased Medicines Co (NASDAQ:MDCO) by $5.73 Million as Shares Declined - Consumer Eagle (NASDAQ:MDCO) - July 16 at 5:46 PM
News IconLarge Inflow of Money Detected in The Medicines Company - TheFounders Daily (NASDAQ:MDCO) - July 15 at 10:32 AM logoThe Medicines Company (NASDAQ:MDCO) Trading Down - Insiders Are Buying and Selling - Finance Daily (NASDAQ:MDCO) - July 14 at 9:43 AM logoThe Medicines Company Realized Volatility Hits a Dropping Level - CML News (NASDAQ:MDCO) - July 12 at 6:22 PM logoMedicines Co. (MDCO) Affirms Positive Appeals Court Decision in Angiomax Patent Case - (NASDAQ:MDCO) - July 12 at 6:22 PM logoAppeals court rules in favor of The Medicines Company in Angiomax patent litigation (NASDAQ:MDCO) - July 12 at 10:44 AM
News IconAnalyst's Report Recap: The Medicines Company (NASDAQ:MDCO) - Post Registrar (NASDAQ:MDCO) - July 12 at 10:29 AM logoThe Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma (NASDAQ:MDCO) - June 30 at 9:30 AM


The Medicines (NASDAQ:MDCO) Chart for Saturday, August, 27, 2016

Last Updated on 8/27/2016 by Staff